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presented for the entire cohort. Univariate and multivariate 
subgroup analysis will be performed to identify possible 
prognostic factors using the log rank test and the Cox 
regression method, respectively. Rates of severe side effects 
and complication rates will be reported descriptively.  
Conclusions: This pooled analysis offers the opportunity to 
evaluate the efficacy and toxicity of a multimodal treatment 
approach including IORT, EBRT and gross total limb-sparing 
surgery in a large series of patients with extremity sarcoma 
treated in European expert centers and therefore may serve 
as a benchmark for other treatment approaches.  
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Purpose/Objective: Patients with locally advanced rectal 
cancer have a dismal prognosis. 
Materials and Methods: We investigated outcomes in 77 
consecutive patients with T4 tumors treated with 
preoperative chemoradiotherapy (CRT), surgery and IOERT. 
Results: Median follow-up was 62.8 months (range, 4-198). 5 
year Loco-regional control, disease-free survival and overall 
survival was 84%, 68% and 65%. 
Conclusions: Overall results after multimodality treatment of 
T4 are promising. Classification of risk factors for LRR would 
contributed to propose a prognostic index that could allow us 
to guide risk-adapted tailored treatment  
 
 
Poster Discussion: Dose modelling and planning  
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Purpose/Objective: In radiotherapy treatment planning for 
patients with tumor relapse, a number of factors must be 
taken into account, such as prior treatments to the area, 
total dose to critical organs, and dose-per-fraction effects 
within the patient volume. The aim of this study was to 
develop a simple tool to explore 3D biological dose 
summation with non-rigid fusion, and to demonstrate its 
importance in treatment planning. 
Materials and Methods: Fine-scale deformable image 
registration was carried out in Mirada RTx™ (Mirada Medical 
Ltd., Oxford, UK), and inspected for plausibility using 
registration QC tools (see Fig 1C). The deformation grids 
were used to transform dose distributions from prior 
treatments into the space of the current target CT. Thus, 
given the number of fractions in each treatment plan, the 
fractional doses for every voxel in the new planning CT 
volume were calculated for each treatment. 
The software used the linear-quadratic (LQ) model for 
equivalence calculations, and doses were expressed as 2Gy 
equivalent dose (EQD2), which were summed voxel-wise to 
give the EQD2 for the total treatment. The interface was 
designed to allow users to specify different alpha/beta-ratios 
per structure on the planning CT, and also to enter a healing 
parameter to down-scale effects of past treatments. 
An illustrative H&N case is presented. A malignancy on the 
left side of the tongue received standard three dose level 
simultaneously integrated boost (SIB) treatment 
(33x2/1.82/1.64Gy at 66/60/54Gy) with a seven field 6MV 
IMRT technique. The planning CT and PTVs are shown in Fig 
1A. Two years after the primary treatment, the patient 
experienced a relapse on the right side, and a 25x2Gy 
treatment was planned for the new PTV (Fig 1B). Even after 
positioning the patient to minimize the difference between 
CTs, the large tissue deformations due to tumor mass and 
neck rigidity presented a challenging registration problem. 
Total doses (in EQD2) to critical organs were investigated, 
using alpha/beta-ratios of 2.1Gy for the medulla, and 3Gy for 
other organs.  
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Results: The maximum doses (in EQD2) for different critical 
organs in the H&N case are presented in Table 1, along with 
doses calculated without deformable registration or 
compensation for biological dose effects. For medulla, 
deformable EQD2 values are approximately 10% less than for 
the rigid raw sum; for other organs the difference varies from 
0 to 8%.  
Conclusions: Considerations of dose to organs at risk may be 
a limiting factor for treatment planning of secondary 
malignancies at the same site. This work has shown a 
complete framework to examine re-treatment planning 
accounting for different patient positions, dose sizes and 
fractionation schemes of new and previous treatments. This 
accurate summed EQD2 distribution is helpful in seeing which 
dose tolerances are reached, and where the treatment plan 
could be modified further. 
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Purpose/Objective: Hyperthermia is still regarded as the 
most potent biological sensitizer for radiotherapy and 
chemotherapy. In addition to positive results multiple phase 
III trials, in many studies a statistical significant relationships 
between applied thermal dose and treatment effectiveness 
were found. The, prospective study of Jones et al. [1] and 
the large, retrospective study of Franckena et al. [2] are 
highly convincing and demonstrate a clear rationale for 
thermal dose escalation. These findings motivated us to 
develop a software to apply HT under objective control of an 
on-line hyperthermia treatment planning (HTP) system. 
International consensus exists that the application of HT will 
benefit strongly from on-line HTP with 3D-visualization and 
control of the heating pattern in the patient. 
Materials and Methods: A software tool called VEDO 
(Visualization tool for Electromagnetic Dosimetry and 
Optimization) was created. The inputs required are: a 3D 
segmentatio of the patient model comprising all tissues, 
target, OAR and pre-calculated electromagnetic fields. VEDO 
calculates Specific Absorption Rate (SAR) distributions and 
performs optimization using a particle swarm (PS) 
optimization algorithm. Spatial optimization weighting 
regions can be manually set. Clinically important quantifiers 
like predicted target SAR dose and maximum allowed power, 
based on SAR in critical tissues, are visualized. 
Results: 
VEDO provides an instant visualization of the SAR-distribution 
(as color wash) over the patients CT using the simulated 
electric fields and real-time measured phase and amplitude 
of the signals fed to each antenna element. Pre-treatment, 
VEDO is used by the MDs for decision making. During 
treatment, VEDO helps the operator to correlate the location 
of pain-complaints to predicted high SAR values near the 
indicated region; allowing re-optimization for reduction of 
the SAR at the indicated 'hot-spot' area. With this, complaint-
adaptive SAR steering is used to convert hotspots in re-
optimized settings, with reduced local SAR, that can directly 
be applied to the patient anatomy. In patients with head and 
neck tumors complaint adaptive SAR steering resulted in at 
least 20% increase of the SAR delivered to the target.  
Conclusions: VEDO is completely objective and quantitative, 
and can be evaluated on its effectiveness. The latter is an 
important step towards abandoning treatment optimization 
based on experience of the hyperthermia staff members. The 
simulations using the patient anatomy also provides much 
more insight as compared to experimental SAR measurements 
in homogeneous phantoms. Clinical application of VEDO 
shows that the workflow is feasible and that re-optimization 
based on patient discomfort is effective in reducing 
complaints.  
1 - Jones EL et al. Randomized trial of hyperthermia and 
radiation for superficial tumors. JCO. 2005, 3079-85. 
2 - Franckena M et al. Hyperthermia dose-effect relationship 
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radiotherapy and hyperthermia. EJC. 2009, 1969-78.  
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Purpose/Objective: To determine the relationship between 
recurrence locations and pre-RT 18F-FDG PET SUV data for 
patients diagnosed with HNSCC. 
Materials and Methods: Based on a patient group of 90 
patients treated with IMRT or VMAT, a retrospective 
investigation of local variations in TCP depending on 
pretreatment 18F-FDG PET SUV through use of recurrence 
